Monterey Bio Acquisition Corporation
MTRYW
NASDAQ Global Market0.00
USD
+0.00
- -
CIK
0001860663
CUSIP
61240F116
Return %
Stock
S&P500
1Y
-98.51
18.44
3Y
-99.94
63.65
5Y
-99.94
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Sanjeev Satyal
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 17 State Street New York City NY United States of America 10004
- IPO Date
- Nov 22, 2021
- CIK
- 0001860663
- Website
- montereybio.com
- Similar Companies
- Business
- Monterey Bio Acquisition Corporation is a special purpose acquisition company (SPAC) focused on effecting mergers, share exchanges, asset acquisitions, stock purchases, recapitalizations, reorganizations, or similar business combinations primarily within the biotechnology sector. The company targets businesses developing or enabling the development of pre-commercial therapeutic candidates across a broad range of therapeutic areas, with an initial focus on oncology and immunology. Founded in 2020 and headquartered in New York, New York, Monterey Bio Acquisition Corporation does not currently have significant operations of its own but operates with the strategic intent to identify and combine with promising biotech firms. It completed an initial public offering raising $100 million, and in 2021 began separate trading of its common stock and warrants under the ticker symbols MTRY and MTRYW respectively. The company rebranded to Monterey Innovation Acquisition Corp. in March 2023 following a share transfer agreement and co-sponsor rebranding initiative. Its business model revolves around facilitating and executing a strategic business combination that accelerates growth and development in targeted biotech areas through mergers or acquisitions. The company operates primarily within the U.S. market but may pursue opportunities in other regions as part of its business combination strategy. It remains focused on identifying and acquiring innovative biotech companies to capitalize on emerging therapeutics and technologies in the life sciences industry.